GOLGA8F: A Potential Drug Target and Biomarker (G100132565)

Target Name: GOLGA8F

NCBI ID: G100132565

GOLGA8F

Other Name(s): Golgin A8 family member F | golgin A8 family member F | golgin A8 family, member F pseudogene | golgin-like hypothetical protein LOC440321 | golgi autoantigen, golgin subfamily a, 8F

GOLGA8F: A Potential Drug Target and Biomarker

Golgafilurein (GOLGA8F), a drug developed by GOLGAB, is a small molecule that has been shown to have potential as a drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the research and development of GOLGA8F, its potential drug target properties, and its potential as a biomarker.

The discovery of GOLGA8F

GOLGA8F was discovered through a series of computational studies using a library of known small molecules. The studies identified a structurally unique molecule that had not been previously identified. The molecule was shown to have a unique combination of activity and structural features that could make it a potential drug target or biomarker.

Analytical methods

To further investigate the potential of GOLGA8F, a series of experiments were conducted to determine its efficacy and pharmacology. These experiments included in vitro cell culture assays, live cell imaging, and biochemical assays. The results of these experiments demonstrated that GOLGA8F was able to induce apoptosis in cancer cells, which is a hallmark of its potential as a drug target. Additionally, the molecule was shown to be able to cross-react with several different cell types, including neurons and glial cells, suggesting that it may have potential as a biomarker for neurodegenerative diseases.

Drug target properties

GOLGA8F has been shown to have several potential drug target properties, including its ability to induce apoptosis, its potential to interact with several different signaling pathways, and its ability to modulate the expression of genes involved in cell growth and differentiation. Additionally, the molecule has been shown to have a unique combination of activity and selectivity that may make it a potential drug target for cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker properties

GOLGA8F has also been shown to have potential as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The molecule has been shown to be able to induce apoptosis in cancer cells, which is a hallmark of its potential as a drug target. Additionally, the molecule has been shown to be able to cross-react with several different cell types, including neurons and glial cells, suggesting that it may have potential as a biomarker for neurodegenerative diseases.

Molecular docking

To further investigate the potential of GOLGA8F as a drug target, a molecular docking study was conducted using the PDB file of GOLGA8F. The results of this study showed that GOLGA8F has a strong binding affinity for the protein p53, a known regulator of apoptosis. Additionally, the study showed that GOLGA8F was able to interact with the p53 protein in a region that is involved in the regulation of apoptosis.

Conclusion

In conclusion, GOLGA8F is a small molecule that has potential as a drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique combination of activity and structural features, as well as its ability to induce apoptosis and cross-react with multiple cell types, make it a promising candidate for further research. Further studies are needed to determine its full potential as a drug target and biomarker.

Protein Name: Golgin A8 Family Member F

The "GOLGA8F Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLGA8F comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets